Present and Future Biochemical Markers for Detection of Acute Coronary Syndrome

REFERENCES

• The Atlas of Heart Disease and Stroke, J Mackay, G Mensah. World Health Organization. 2004, Also found at http://www.who.int/cardiovascular_diseases/resources/atlas/en/. Last accessed June 26, 2006
   Google Scholar
• Davies M J. The pathophysiology of cute coronary syndromes. Heart 2000; 83: 361–366, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Alpert J S, Thygesen K, Antman E, Bassand J P. Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959–969, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bertrand M E, Simoons M L, Fox K A, Wallentin L C, Hamm C W, McFadden E, De Feyter P J, Specchia G, Ruzyllo W. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809–1840, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Van de Werf F, Ardissino D, Betriu A, Cokkinos D V, Falk E, Fox K A, Julian D, Lengyel M, Neumann F J, Ruzyllo W, Thygesen C, Underwood S R, Vahanian A, Verheugt F W, Wijns W. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of The European Society of Cardiology. Eur Heart J 2003; 24: 28–66, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• LaDue J S, Wroblewski F, Karmen A. Serum glutamic oxaloacetic transaminase activity in human acute transmural myocardial infarction. Science 1954; 120: 497–499, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rioufol G, Finet G, Ginon I, Andre-Fouet X, Rossi R, Vialle E, Desjoyaux E, Convert G, Huret J F, Tabib A. Multiple atherosclerotic plaque rupture in acute coronary syndrome: A three-vessel intravascular ultrasound study. Circulation 2002; 106: 804–808, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hong M K, Mintz G S, Lee C W, Kim Y H, Lee S W, Song J M, Han K H, Kang D H, Song J K, Kim J J, Park S W, Park S J. Comparison of coronary plaque rupture between stable angina and acute myocardial infarction: A three-vessel intravascular ultrasound study in 235 patients. Circulation 2004; 110: 928–933, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Braunwald E, Antman E M, Beasley J W, Califf R M, Cheitlin M D, Hochman J S, Jones R H, Kereiakes D, Kupersmith J, Levin T N. ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the management of patients with unstable angina). J Am Coll Cardiol 2000; 36: 970–1062, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis—An inflammatory disease. N Engl J Med 1999; 340: 115–126, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365–372, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Monaco C, Mathur A, Martin J F. What causes acute coronary syndromes? Applying Koch's postulates. Atherosclerosis 2005; 179: 1–15, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Lusis A J. Atherosclerosis. Nature 2000; 407: 233–241, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cai H, Harrison D G. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 2000; 87: 840–844, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Naghavi M, Libby P, Falk E, Casscells S W, Litovsky S, Rumberger J, Badimon J J, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone P H, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald P J, Siscovick D S, de Korte C L, Aikawa M, Juhani Airaksinen K E, Assmann G, Becker C R, Chesebro J H, Farb A, Galis Z S, Jackson C, Jang I K, Koenig W, Lodder R A, March K, Demirovic J, Navab M, Priori S G, Rekhter M D, Bahr R, Grundy S M, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W, Jr, Schwartz R S, Vogel R, Serruys P W, Hansson G K, Faxon D P, Kaul S, Drexler H, Greenland P, Muller J E, Virmani R, Ridker P M, Zipes D P, Shah P K, Willerson J T. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664–1672, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Shah P K. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003; 41(4 Suppl S)15S–22S, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Vink A, Pasterkamp G. Atherosclerotic plaques: How vulnerable is the definition of “the vulnerable plaque”?. J Interv Cardiol 2003; 16: 115–122, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Gregoratos G. Clinical manifestations of acute myocardial infarction in older patients. Am J Geriatr Cardiol 2001; 10: 345–347, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Airaksinen K E. Silent coronary artery disease in diabetes—a feature of autonomic neuropathy or accelerated atherosclerosis?. Diabetologia 2001; 44: 259–266, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Yusuf P S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364: 937–952, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wu A H, Apple F S, Gibler W B, Jesse R L, Warshaw M M, Valdes R, Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999; 45: 1104–1121, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wroblewski F, LaDue J S. Lactic dehydrogenase activity in blood. Proc Soc Exp Biol Med 1955; 90: 210–213, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dreyfus J C, Schapira G, Resnais J, Scebat L. Serum creatine kinase in the diagnosis of myocardial infarct. [Article in French]. Rev Fr Etud Clin Biol 1960; 5: 386–387, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Oliver I T. A spectrophotometric method for the determination of creatine phosphokinase and myokinase. Biochem J 1955; 61: 116–122, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rosalki S B. An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med 1967; 69: 696–705, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Roe C R, Limbird L E, Wagner G S, Nerenberg S T. Combined isoenzyme analysis in the diagnosis of myocardial injury: Application of electrophoretic methods for the detection and quantitation of the creatine phosphokinase MB isoenzyme. J Lab Clin Med 1972; 80: 577–590, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Jockers W, Wretou E, Pfleiderer G. Quantitation of creatine kinase isoenzymes in human tissues and sera by an immunological method. Clin Chim Acta 1975; 58: 223–232, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Freeman I, Opher A W. Lactic dehydrogenase isoenzymes in myocardial infarction. Am J Med Sci 1965; 250: 131–136, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Cohen L, Djordjevich J, Jacobsen S. The contribution of isozymes of serum lactic dehydrogenase (LDH) to the diagnosis of specific organ injury with special reference to myocardial injury. Med Clin North Am 1966; 50: 193–209, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Di Giorgio J. Determination of serum lactic dehydrogenase isoenzymes by use of the “Diagnostest” cellulose acetate electrophoresis system. Clin Chem 1971; 17: 326–331, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Usategui-Gomez M, Wicks R W, Warshaw M. Immunochemical determination of the heart isoenzyme of lactate dehydrogenase (LDH1) in human serum. Clin Chem 1979; 25: 729–734, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Stone M J, Willerson J T, Gomez-Sanchez C E, Waterman M R. Radioimmunoassay of myoglobin in human serum. Results in patients with acute myocardial infarction. J Clin Invest 1975; 56: 1334–1339, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Delanghe J R, Chapelle J P, Vanderschueren S C. Quantitative nephelometric assay for determining myoglobin evaluated. Clin Chem 1990; 36: 1675–1678, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Borque L, Rus A, Ruiz R. Quantitative automated latex nephelometric immunoassay for determination of myoglobin in human serum. J Clin Lab Anal 1991; 5: 175–179, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Chan D W, Taylor E, Frye R, Blitzer R L. Immunoenzymetric assay for creatine kinase MB with subunit-specific monoclonal antibodies compared with an immunochemical method and electrophoresis. Clin Chem 1985; 31: 465–469, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Vaidya H C, Maynard Y, Dietzler D N, Ladenson J H. Direct measurement of creatine kinase-MB activity in serum after extraction with a monoclonal antibody specific to the MB isoenzyme. Clin Chem 1986; 32: 657–663, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cummins B, Auckland M L, Cummins P. Cardiac-specific troponin-I radioimmunoassay in the diagnosis of acute myocardial infarction. Am Heart J 1987; 113: 1333–1344, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Katus H A, Remppis A, Looser S, Hallermeier K, Scheffold T, Kubler W. Enzyme linked immuno assay of cardiac troponin T for the detection of acute myocardial infarction in patients. J Mol Cell Cardiol 1989; 21: 1349–1353, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bodor G S, Porter S, Landt Y, Ladenson J H. Development of monoclonal antibodies for an assay of cardiac troponin-I and preliminary results in suspected cases of myocardial infarction. Clin Chem 1992; 38: 2203–2214, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tanaka T, Hirota Y, Sohmiya K, Nishimura S, Kawamura K. Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction. Clin Biochem 1991; 24: 195–201, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kleine A H, Glatz J F, Van Nieuwenhoven F A, Van der Vusse G J. Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem 1992; 116: 155–162, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tsuji R, Tanaka T, Sohmiya K, Hirota Y, Yoshimoto K, Kinoshita K, Kusaka Y, Kawamura K, Morita H, Abe S. Human heart-type cytoplasmic fatty acid-binding protein in serum and urine during hyperacute myocardial infarction. Int J Cardiol 1993; 41: 209–217, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pelsers M MAL, Hermens W T, Glatz J FC. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005; 352: 15–35, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hein S, Scheffold T, Schaper J. Ischemia induces early changes to cytoskeletal and contractile proteins in diseased human myocardium. J Thorac Cardiovasc Surg 1995; 110: 89–98, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Adams J E, 3rd, Abendschein D R, Jaffe A S. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s?. Circulation 1993; 88: 750–763, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Donnelly R, Millar-Craig M W. Cardiac troponins: IT upgrade for the heart. Lancet 1998; 351: 537–539, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kemp M, Donovan J, Higham H, Hooper J. Biochemical markers of myocardial injury. Br J Anaesth 2004; 93: 63–73, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Farah C, Reinach F. The troponin complex and regulation of muscle contraction. FASEB J 1995; 9: 755–767, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gomes A V, Potter J D, Szczesna-Cordary D. The role of troponins in muscle contraction. IUBMB Life 2002; 54: 323–333, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sasse S, Brand N, Kyprianou P, Dhoot G, Wade R, Arai M, Periasamy M, Yacoub M, Barton P. Troponin I gene expression during human cardiac development and in end-stage heart failure. Circ Res 1993; 72: 932–938, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bodor G, Porterfield D, Voss E, Smith S, Apple F. Cardiac troponin-I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue. Clin Chem 1995; 41: 1710–1715, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Breitbart R E, Nguyen H T, Medford R M, Destree A T, Mahdavi V, Nadal-Ginard B. Intricate combinatorial patterns of exon splicing generate multiple regulated troponin T isoforms from a single gene. Cell 1985; 41: 67–82, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Cooper T A, Ordahl C P. A single cardiac troponin T gene generates embryonic and adult isoforms via developmentally regulated alternate splicing. J Biol Chem 1985; 260: 11140–11148, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Anderson P, Malouf N, Oakeley A, Pagani E, Allen P. Troponin T isoform expression in humans. A comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle. Circ Res 1991; 69: 1226–1233, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Schreier T, Kedes L, Gahlmann R. Cloning, structural analysis, and expression of the human slow twitch skeletal muscle/cardiac troponin C gene. J Biol Chem 1990; 265: 21247–21253, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Gahlmann R, Kedes L. Cloning, structural analysis, and expression of the human fast twitch skeletal muscle troponin C gene. J Biol Chem 1990; 265: 12520–12528, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Takeda S, Yamashita A, Maeda K, Maeda Y. Structure of the core domain of human cardiac troponin in the Ca(2+)-saturated form. Nature 2003; 424: 35–41, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Swiderek K, Jaquet K, Meyer H E, Schachtele C, Hofmann F, Heilmeyer L M, Jr. Sites phosphorylated in bovine cardiac troponin T and Characterization I. by 31P-NMR spectroscopy and phosphorylation by protein kinases. Eur J Biochem 1990; 190: 575–582, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• McConnell B K, Moravec C S, Morano I, Bond M. Troponin I phosphorylation in spontaneously hypertensive rat heart: Effect of beta-adrenergic stimulation. Am J Physiol 1997; 273: H1440–H1451, [INFOTRIEVE], [CSA]
   Google Scholar
• Malhotra A, Nakouzi A, Bowman J, Buttrick P. Expression and regulation of mutant forms of cardiac TnI in a reconstituted actomyosin system: Role of kinase dependent phosphorylation. Mol Cell Biochem 1997; 170: 99–107, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• al-Hillawi E, Bhandari D G, Trayer H R, Trayer I P. The effects of phosphorylation of cardiac troponin-I on its interactions with actin and cardiac troponin-C. Eur J Biochem 1995; 228: 962–970, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Jideama N M, Noland T A, Jr, Raynor R L, Blobe G C, Fabbro D, Kazanietz M G, Blumberg P M, Hannun Y A, Kuo J F. Phosphorylation specificities of protein kinase C isozymes for bovine cardiac troponin I and troponin T and sites within these proteins and regulation of myofilament properties. J Biol Chem 1996; 271: 23277–23283, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Noland T A, Jr, Raynor R L, Jideama N M, Guo X, Kazanietz M G, Blumberg P M, Solaro R J, Kuo J F. Differential regulation of cardiac actomyosin S-1 MgATPase by protein kinase C isozyme-specific phosphorylation of specific sites in cardiac troponin I and its phosphorylation site mutants. Biochemistry 1996; 35: 14923–14931, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Noland T A, Jr, Guo X, Raynor R L, Jideama N M, Averyhart-Fullard V, Solaro R J, Kuo J F. Cardiac troponin I mutants. Phosphorylation by protein kinases C and A and regulation of Ca(2+)-stimulated MgATPase of reconstituted actomyosin S-1. J Biol Chem 1995; 270: 25445–25454, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Vallins W J, Brand N J, Dabhade N, Butler-Browne G, Yacoub M H, Barton P J. Molecular cloning of human cardiac troponin I using polymerase chain reaction. FEBS Lett 1990; 270: 57–61, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ingraham R H, Hodges R S. Effects of Ca2+ and subunit interactions on surface accessibility of cysteine residues in cardiac troponin. Biochemistry 1988; 27: 5891–5898, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Gagne S M, Tsuda S, Li M X, Smillie L B, Sykes B D. Structures of the troponin C regulatory domains in the apo and calcium-saturated states. Nat Struct Biol 1995; 2: 784–789, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Spyracopoulos L, Li M X, Sia S K, Gagne S M, Chandra M, Solaro R J, Sykes B D. Calcium-induced structural transition in the regulatory domain of human cardiac troponin C. Biochemistry 1997; 36: 12138–12146, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Potter J D, Gergely J. The calcium and magnesium binding sites on troponin and their role in the regulation of myofibrillar adenosine triphosphatase. J Biol Chem 1975; 250: 4628–4633, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Robertson S P, Johnson J D, Holroyde M J, Kranias E G, Potter J D, Solaro R J. The effect of troponin I phosphorylation on the Ca2+-binding properties of the Ca2+-regulatory site of bovine cardiac troponin. J Biol Chem 1982; 257: 260–263, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Perry S V. Troponin T: Genetics, properties and function. J Muscle Res Cell Motil 1998; 19: 575–602, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Potter J D, Sheng Z, Pan B S, Zhao J. A direct regulatory role for troponin T and a dual role for troponin C in the Ca2+ regulation of muscle contraction. J Biol Chem 1995; 270: 2557–2562, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Ingraham R H, Swenson C A. Binary interactions of troponin subunits. J Biol Chem 1984; 259: 9544–9548, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Chong P, Hodges R. Photochemical cross-linking between rabbit skeletal troponin subunits. Troponin I-troponin T interactions. J Biol Chem 1982; 257: 11667–11672, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Voss E M, Sharkey S W, Gernert A E, Murakami M M, Johnston R B, Hsieh C C, Apple F S. Human and canine cardiac troponin T and creatine kinase-MB distribution in normal and diseased myocardium. Infarct sizing using serum profiles. Arch Pathol Lab Med 1995; 119: 799–806, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bleier J, Vorderwinkler K P, Falkensammer J, Mair P, Dapunt O, Puschendorf B, Mair J. Different intracellular compartmentations of cardiac troponins and myosin heavy chains: A causal connection to their different early release after myocardial damage. Clin Chem 1998; 44: 1912–1918, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mair J, Genser N, Morandell D, Maier J, Mair P, Lechleitner P, Calzolari C, Larue C, Ambach E, Dienstl F, Pau B, Puschendorf B. Cardiac troponin I in the diagnosis of myocardial injury and infarction. Clin Chim Acta 1996; 245: 19–38, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Katus H A, Remppis A, Scheffold T, Diederich K W, Kuebler W. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol 1991; 67: 1360–1367, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bertinchant J P, Larue C, Pernel I, Ledermann B, Fabbro-Peray P, Beck L, Calzolari C, Trinquier S, Nigond J, Pau B. Release kinetics of serum cardiac troponin I in ischemic myocardial injury. Clin Biochem 1996; 29: 587–594, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Jaffe A S, Ravkilde J, Roberts R, Naslund U, Apple F S, Galvani M, Katus H. It's time for a change to a troponin standard. Circulation 2000; 102: 1216–1220, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wu A H, Ford L. Release of cardiac troponin in acute coronary syndromes: Ischemia or necrosis?. Clin Chim Acta 1999; 284: 161–174, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wu A H. Increased troponin in patients with sepsis and septic shock: Myocardial necrosis or reversible myocardial depression?. Intensive Care Med 2001; 27: 959–961, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Brett J, Gerlach H, Nawroth P, Steinberg S, Godman G, Stern D. Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med 1989; 169: 1977–1991, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hamm C W, Ravkilde J, Gerhardt W, Jorgensen P, Peheim E, Ljungdahl L, Goldmann B, Katus H A. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992; 327: 146–150, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Feng Y J, Chen C, Fallon J T, Lai T, Chen L, Knibbs D R, Waters D D, Wu A H. Comparison of cardiac troponin I, creatine kinase-MB, and myoglobin for detection of acute ischemic myocardial injury in a swine model. Am J Clin Pathol 1998; 110: 70–77, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Newby L K, Storrow A B, Gibler W B, Garvey J L, Tucker J F, Kaplan A L, Schreiber D H, Tuttle R H, McNulty S E, Ohman E M. Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation 2001; 103: 1832–1837, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• McCord J, Nowak R M, McCullough P A, Foreback C, Borzak S, Tokarski G, Tomlanovich M C, Jacobsen G, Weaver W D. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation 2001; 104: 1483–1488, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ottani F, Galvani M, Nicolini F A, Ferrini D, Pozzati A, Di Pasquale G, Jaffe A S. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000; 140: 917–927, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Heidenreich P A, Alloggiamento T, Melsop K, McDonald K M, Go A S, Hlatky M A. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: A meta-analysis. J Am Coll Cardiol 2001; 38: 478–485, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Christenson R H, Duh S H, Newby L K, Ohman E M, Califf R M, Granger C B, Peck S, Pieper K S, Armstrong P W, Katus H A, Topol E J. Cardiac troponin T and cardiac troponin I: Relative values in short-term risk stratification of patients with acute coronary syndromes. Global use of Strategies to Open Occluded Coronary Artries. GUSTO-IIa Investigators. Clin Chem 1998; 44: 494–501, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Morrow D A, Antman E M, Tanasijevic M, Rifai N, de Lemos J A, McCabe C H, Cannon C P, Braunwald E. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: A TIMI-11B substudy. J Am Coll Cardiol 2000; 36: 1812–1817, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. Fragmin during Instability in Coronary (FRCIS) Artery Disease Study Group. N Engl J Med 2000; 343: 1139–1147, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ohman E M, Armstrong P W, Christenson R H, Granger C B, Katus H A, Hamm C W, O'Hanesian M A, Wagner G S, Kleiman N S, Harrell F E, Jr, Califf R M, Topol E J. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. N Engl J Med 1996; 335: 1333–1341, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ohman E M, Armstrong P W, White H D, Granger C B, Wilcox R G, Weaver W D, Gibler W B, Stebbins A L, Cianciolo C, Califf R M, Topol E J. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. Am J Cardiol 1999; 84: 1281–1286, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dokainish H, Pillai M, Murphy S A, DiBattiste P M, Schweiger M J, Lotfi A, Morrow D A, Cannon C P, Braunwald E, Lakkis N. Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: A TACTICS-TIMI-18 substudy. J Am Coll Cardiol 2005; 45: 19–24, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol 1997; 29: 43–48, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hamm C W, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel C M, Rutsch W, Berger J, Kootstra J, Simoons M L. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999; 340: 1623–1629, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Heeschen C, Hamm C W, Goldmann B, Deu A, Langenbrink L, White H D. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. Lancet 1999; 354: 1757–1762, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Newby L K, Ohman E M, Christenson R H, Moliterno D J, Harrington R A, White H D, Armstrong P W, Van De Werf F, Pfisterer M, Hasselblad V, Califf R M, Topol E J. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: The paragon-B troponin T substudy. Circulation 2001; 103: 2891–2896, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Januzzi J L, Chae C U, Sabatine M S, Jang I K. Elevation in serum troponin I predicts the benefit of tirofiban. J Thromb Thrombolysis 2001; 11: 211–215, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Boersma E, Harrington R A, Moliterno D J, White H, Theroux P, Van de Werf F, de Torbal A, Armstrong P W, Wallentin L C, Wilcox R G, Simes J, Califf R M, Topol E J, Simoons M L. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189–198, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Morrow D A, Cannon C P, Rifai N, Frey M J, Vicari R, Lakkis N, Robertson D H, Hille D A, DeLucca P T, DiBattiste P M, Demopoulos L A, Weintraub W S, Braunwald E. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: Results from a randomized trial. JAMA 2001; 286: 2405–2412, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• No authors listed. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354: 708–715, [CSA]
   PubMedGoogle Scholar
• Bhayana V, Gougoulias T, Cohoe S, Henderson A R. Discordance between results for serum troponin T and troponin I in renal disease. Clin Chem 1995; 41: 312–317, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Collinson P O, Stubbs P J, Rosalki S B. Cardiac troponin T in renal disease. Clin Chem 1995; 41: 1671–1673, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Collinson P O, Hadcocks L, Foo Y, Rosalki S B, Stubbs P J, Morgan S H, O'Donnell J. Cardiac troponins in patients with renal dysfunction. Ann Clin Biochem 1998; 35: 380–386, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Roppolo L P, Fitzgerald R, Dillow J, Ziegler T, Rice M, Maisel A. A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at a Veteran's Hospital: A pilot study. J Am Coll Cardiol 1999; 34: 448–454, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Apple F S, Murakami M M, Pearce L A, Herzog C A. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002; 106: 2941–2945, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Apple F S, Murakami M M, Pearce L A, Herzog C A. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004; 50: 2279–2285, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sharma R, Gaze D C, Pellerin D, Metha R, Gregson H, Streather C P, Collinson P O, Brecker S J. Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T. Heart 2006; 92: 804–809, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• McLaurin M D, Apple F S, Voss E M, Herzog C A, Sharkey S W. Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialysis patients without ischemic heart disease: Evidence of cardiac troponin T expression in skeletal muscle. Clin Chem 1997; 43: 976–982, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Apple F S, Sharkey S W, Hoeft P, Skeate R, Voss E, Dahlmeier B A, Preese L M. Prognostic value of serum cardiac troponin I and T in chronic dialysis patients: A 1-year outcomes analysis. Am J Kidney Dis 1997; 29: 399–403, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gupta M, Lent R W, Kaplan E L, Zabriskie J B. Serum cardiac troponin I in acute rheumatic fever. Am J Cardiol 2002; 89: 779–782, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cantwell R V, Aviles R J, Bjornsson J, Wright R S, Freeman W K, Oh J K, Hoyer J D, Markovic S, Jaffe A S. Cardiac amyloidosis presenting with elevations of cardiac troponin I and angina pectoris. Clin Cardiol 2002; 25: 33–37, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle R A, Gertz M A, Therneau T M, Miller W L, Chandrasekaran K, McConnell J P, Burritt M F, Jaffe A S. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361: 1787–1789, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ferjani M, Droc G, Dreux S, Arthaud M, Goarin J P, Riou B, Coriat P. Circulating cardiac troponin T in myocardial contusion. Chest 1997; 111: 427–433, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Ognibene A, Mori F, Santoni R, Zuppiroli A, Peris A, Targioni G, Dolara A. Cardiac troponin I in myocardial contusion. Clin Chem 1998; 44: 889–890, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Sybrandy K C, Cramer M J, Burgersdijk C. Diagnosing cardiac contusion: Old wisdom and new insights. Heart 2003; 89: 485–489, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Allan J J, Feld R D, Russell A A, Ladenson J H, Rogers M A, Kerber R E, Jaffe A S. Cardiac troponin I levels are normal or minimally elevated after transthoracic cardioversion. J Am Coll Cardiol 1997; 30: 1052–1056, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dworschak M, Franz M, Khazen C, Czerny M, Haisjackl M, Hiesmayr M. Mechanical trauma as the major cause of troponin T release after transvenous implantation of cardioverter/defibrillators. Cardiology 2001; 95: 212–214, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Kannankeril P J, Pahl E, Wax D F. Usefulness of troponin I as a marker of myocardial injury after pediatric cardiac catheterization. Am J Cardiol 2002; 90: 1128–1132, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cardinale D, Sandri M T, Martinoni A, Tricca A, Civelli M, Lamantia G, Cinieri S, Martinelli G, Cipolla C M, Fiorentini C. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517–522, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pateron D, Beyne P, Laperche T, Logeard D, Lefilliatre P, Sogni P, Moreau R, Langlet P, Elman A, Bernuau J, Valla D, Erlinger S, Lebrec D. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 1999; 29: 640–643, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sato Y, Yamada T, Taniguchi R, Nagai K, Makiyama T, Okada H, Kataoka K, Ito H, Matsumori A, Sasayama S, Takatsu Y. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001; 103: 369–374, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• La Vecchia L, Mezzena G, Zanolla L, Paccanaro M, Varotto L, Bonanno C, Ometto R. Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. J Heart Lung Transplant 2000; 19: 644–652, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Horwich T B, Patel J, MacLellan W R, Fonarow G C. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108: 833–838, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wright R S, Williams B A, Cramner H, Gallahue F, Willmore T, Lewis L, Ladenson J H, Jaffe A S. Elevations of cardiac troponin I are associated with increased short-term mortality in noncardiac critically ill emergency department patients. Am J Cardiol 2002; 90: 634–636, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Ammann P, Maggiorini M, Bertel O, Haenseler E, Joller-Jemelka H I, Oechslin E, Minder E I, Rickli H, Fehr T. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol 2003; 41: 2004–2009, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chance J J, Segal J B, Wallerson G, Kasper E, Hruban R H, Kickler T S, Chan D W. Cardiac troponin T and C-reactive protein as markers of acute cardiac allograft rejection. Clin Chim Acta 2001; 312: 31–39, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Fleming S M, O'Gorman T, Finn J, Grimes H, Daly K, Morrison J J. Cardiac troponin I in pre-eclampsia and gestational hypertension. BJOG 2000; 107: 1417–1420, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Smith S C, Ladenson J H, Mason J W, Jaffe A S. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation 1997; 95: 163–168, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Franz W M, Remppis A, Kandolf R, Kubler W, Katus H A. Serum troponin T: Diagnostic marker for acute myocarditis. Clin Chem 1996; 42: 340–341, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lauer B, Niederau C, Kuhl U, Schannwell M, Pauschinger M, Strauer B E, Schultheiss H P. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 1997; 30: 1354–1359, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bonnefoy E, Godon P, Kirkorian G, Fatemi M, Chevalier P, Touboul P. Serum cardiac troponin I and ST-segment elevation in patients with acute pericarditis. Eur Heart J 2000; 21: 832–836, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Brandt R R, Filzmaier K, Hanrath P. Circulating cardiac troponin I in acute pericarditis. Am J Cardiol 2001; 87: 1326–1328, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Lopez-Jimenez F, Goldman L, Sacks D B, Thomas E J, Johnson P A, Cook E F, Lee T H. Prognostic value of cardiac troponin T after noncardiac surgery: 6-month follow-up data. J Am Coll Cardiol 1997; 29: 1241–1245, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Giannitsis E, Muller-Bardorff M, Kurowski V, Weidtmann B, Wiegand U, Kampmann M, Katus H A. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 2000; 102: 211–217, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mehta N J, Jani K, Khan I A. Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J 2003; 145: 821–825, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Spies C, Haude V, Fitzner R, Schroder K, Overbeck M, Runkel N, Schaffartzik W. Serum cardiac troponin T as a prognostic marker in early sepsis. Chest 1998; 113: 1055–1063, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Fernandes C J, Jr, Akamine N, Knobel E. Cardiac troponin: A new serum marker of myocardial injury in sepsis. Intensive Care Med 1999; 25: 1165–1168, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• ver Elst K M, Spapen H D, Nguyen D N, Garbar C, Huyghens L P, Gorus F K. Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem 2000; 46: 650–657, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ammann P, Fehr T, Minder E I, Gunter C, Bertel O. Elevation of troponin I in sepsis and septic shock. Intensive Care Med 2001; 27: 965–969, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rifai N, Douglas P S, O'Toole M, Rimm E, Ginsburg G S. Cardiac troponin T and I, electrocardiographic wall motion analyses, and ejection fractions in athletes participating in the Hawaii Ironman Triathlon. Am J Cardiol 1999; 83: 1085–1089, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Neumayr G, Gaenzer H, Pfister R, Sturm W, Schwarzacher S P, Eibl G, Mitterbauer G, Hoertnagl H. Plasma levels of cardiac troponin I after prolonged strenuous endurance exercise. Am J Cardiol 2001; 87: 369–371, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Collinson P O, Stubbs P J. Are troponins confusing?. Heart 2003; 89: 1285–1287, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur Heart J 2004; 25: 1187–1196, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Katrukha A G, Bereznikova A V, Esakova T V, Pettersson K, Lövgren T, Severina M E, Pulkki K, Vuopio-Pulkki L M, Gusev N B. Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex. Clin Chem 1997; 43: 1379–1385, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wu A HB, Feng Y J, Moore R, Apple F S, McPherson P H, Buechler K F, Bodor G, American Association for Clinical Chemistry Subcommittee on cTnI Standardization. Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I. Clin Chem 1998; 44: 1198–1208, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Giuliani I, Bertinchant J P, Granier C, Laprade M, Chocron S, Toubin G, Etievent J P, Larue C, Trinquier S. Determination of cardiac troponin I forms in the blood of patients with acute myocardial infarction and patients receiving crystalloid or cold blood cardioplegia. Clin Chem 1999; 45: 213–222, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Giuliani I, Bertinchant J P, Lopez M, Coquelin H, Granier C, Laprade M, Pau B, Larue C. Determination of cardiac troponin I forms in the blood of patients with unstable angina pectoris. Clin Biochem 2002; 35: 111–117, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Morjana N A. Degradation of human cardiac troponin I after myocardial infarction. Biotechnol Appl Biochem 1998; 28: 105–111, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Labugger R, Simpson J A, Quick M, Brown H A, Collier C E, Neverova I, Van Eyk J E. Strategy for analysis of cardiac troponins in biological samples with a combination of affinity chromatography and mass spectrometry. Clin Chem 2003; 49: 873–879, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• McDonough J L, Arrell D K, Van Eyk J E. Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury. Circ Res 1999; 84: 9–20, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Labugger R, Organ L, Collier C, Atar D, Van Eyk J E. Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation 2000; 102: 1221–1226, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• McDonough J L, Labugger R, Pickett W, Tse M Y, MacKenzie S, Pang S C, Atar D, Ropchan G, Van Eyk J E. Cardiac troponin I is modified in the myocardium of bypass patients. Circulation 2001; 103: 58–64, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Di Lisa F, De Tullio R, Salamino F, Barbato R, Melloni E, Siliprandi N, Schiaffino S, Pontremoli S. Specific degradation of troponin T and I by mu-calpain and its modulation by substrate phosphorylation. Biochem J 1995; 308: 57–61, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Katrukha A G, Bereznikova A V, Filatov V L, Esakova T V, Kolosova O V, Pettersson K, Lövgren T, Bulargina T V, Trifonov I R, Gratsiansky N A, Pulkki K, Voipio-Pulkki L M, Gusev N B. Degradation of cardiac troponin I: Implication for reliable immunodetection. Clin Chem 1998; 44: 2433–2440, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Colantonio D A, Pickett W, Brison R J, Collier C E, Van Eyk J E. Detection of cardiac troponin I early after onset of chest pain in six patients. Clin Chem 2002; 48: 668–671, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shi Q, Ling M, Zhang X, Zhang M, Kadijevic L, Liu S, Laurino J P. Degradation of cardiac troponin I in serum complicates comparisons of cardiac troponin I assays. Clin Chem 1999; 45: 1018–1025, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Law W R, Ross J D, Jonjev Z S. Adenosine attenuates C-terminal but not N-terminal proteolysis of cTnI during cardioplegic arrest. J Surg Res 2005; 123: 126–133, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Katrukha A, Bereznikova A, Filatov V, Esakova T. Biochemical factors influencing measurement of cardiac troponin I in serum. Clin Chem Lab Med 1999; 37: 1091–1095, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Datta P, Foster K, Dasgupta A. Comparison of immunoreactivity of five human cardiac troponin I assays toward free and complexed forms of the antigen: Implications for assay discordance. Clin Chem 1999; 45: 2266–2269, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Katrukha A, Bereznikova A, Pettersson K. New approach to standardisation of human cardiac troponin I (cTnI). Scand J Clin Lab Invest Suppl 1999; 230: 124–127, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Collinson P O, Boa F G, Gaze D C. Measurement of cardiac troponins. Ann Clin Biochem 2001; 38: 423–449, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Uettwiller-Geiger D, Wu A H, Apple F S, Jevans A W, Venge P, Olson M D, Darte C, Woodrum D L, Roberts S, Chan S. Multicenter evaluation of an automated assay for troponin I. Clin Chem 2002; 48: 869–876, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Venge P, Lindahl B, Wallentin L. New generation cardiac troponin I assay for the Access immunoassay system. Clin Chem 2001; 47: 959–961, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• al-Hillawi E, Chilton D, Trayer I P, Cummins P. Phosphorylation-specific antibodies for human cardiac troponin-I. Eur J Biochem 1998; 256: 535–540, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Hedberg P, Valkama J, Puukka M. Analytical performance of time-resolved fluorometry-based Innotrac Aio! cardiac marker immunoassays. Scand J Clin Lab Invest 2003; 63: 55–64, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Gerhardt W, Nordin G, Herbert A K, Burzell B L, Isaksson A, Gustavsson E, Haglund S, Muller-Bardorff M, Katus H A. Troponin T and I assays show decreased concentrations in heparin plasma compared with serum: Lower recoveries in early than in late phases of myocardial injury. Clin Chem 2000; 46: 817–821, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Stiegler H, Fischer Y, Vazquez-Jimenez J F, Graf J, Filzmaier K, Fausten B, Janssens U, Gressner A M, Kunz D. Lower cardiac troponin T and I results in heparin-plasma than in serum. Clin Chem 2000; 46: 1338–1344, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Speth M, Seibold K, Katz N. Interaction between heparin and cardiac troponin T and troponin I from patients after coronary bypass surgery. Clin Biochem 2002; 35: 355–362, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Pagani F, Stefini F, Chapelle J P, Lefevre G, Graine H, Luthe H, Engelmayer J, Panteghini M. Multicenter evaluation of analytical performance of the Liaison troponin I assay. Clin Biochem 2004; 37: 750–757, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Di Serio F, Trerotoli P, Serio G, Varraso L, Pansini N. Analytical evaluation of an automated immunoassay for cardiac troponin I: The Vidas Troponin I assay. Clin Chem Lab Med 2003; 41: 1363–1368, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Nosanchuk J S, Combs B, Abbott G. False increases of troponin I attributable to incomplete separation of serum. Clin Chem 1999; 45: 714, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Selby C. Interference in immunoassay. Ann Clin Biochem 1999; 36: 704–721, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Weber T H, Kapyaho K I, Tanner P. Endogenous interference in immunoassays in clinical chemistry. A review. Scand J Clin Lab Invest Suppl 1990; 201: 77–82, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Kricka L J. Human anti-animal antibody interferences in immunological assays. Clin Chem 1999; 45: 942–956, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kaplan I V, Levinson S S. When is a heterophile antibody not a heterophile antibody? When it is an antibody against a specific immunogen?. Clin Chem 1999; 45: 616–618, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lind P, Lechner P, Arian-Schad K, Klimpfinger M, Cesnik H, Kammerhuber F, Eber O. Anti-carcinoembryonic antigen immunoscintigraphy (technetium-99m-monoclonal antibody BW 431/26) and serum CEA levels in patients with suspected primary and recurrent colorectal carcinoma. J Nucl Med 1991; 32: 1319–1325, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Börmer O P. Interference of complement with the binding of carcinoembryonic antigen to solid-phase monoclonal antibodies. J Immunol Methods 1989; 121: 85–93, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Després N, Grant A M. Antibody interference in thyroid assays: A potential for clinical misinformation. Clin Chem 1998; 44: 440–454, [CSA]
   PubMed Web of Science ®Google Scholar
• Csako G, Weintraub B D, Zweig M H. The potency of immunoglobulin G fragments for inhibition of interference caused by anti-immunoglobulin antibodies in a monoclonal immunoradiometric assay for thyrotropin. Clin Chem 1988; 34: 1481–1483, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Vaidya H C, Beatty B G. Eliminating interference from heterophilic antibodies in a two-site immunoassay for creatine kinase MB by using F(ab′)2 conjugate and polyclonal mouse IgG. Clin Chem 1992; 38: 1737–1742, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Eriksson S, Vehniäinen M, Jansén T, Meretoja V, Saviranta P, Pettersson K, Lövgren T. Dual-label time-resolved immunofluorometric assay of free and total prostate-specific antigen based on recombinant Fab fragments. Clin Chem 2000; 46: 658–666, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Warren D J, Bjerner J, Paus E, Bormer O P, Nustad K. Use of an in vivo biotinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies. Clin Chem 2005; 51: 830–838, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Eriksson S, Junikka M, Laitinen P, Majamaa-Voltti K, Alfthan H, Pettersson K. Negative interference in cardiac troponin I immunoassays from a frequently occurring serum and plasma component. Clin Chem 2003; 49: 1095–1104, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Eriksson S, Junikka M, Pettersson K. An interfering component in cardiac troponin I immunoassays—its nature and inhibiting effect on the binding of antibodies against different epitopes. Clin Biochem 2004; 37: 472–480, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Eriksson S, Halenius H, Pulkki K, Hellman J, Pettersson K. Negative interference in cardiac troponin I immunoassays by circulating troponin autoantibodies. Clin Chem 2005; 51: 839–847, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Eriksson S, Hellman J, Pettersson K. Autoantibodies against cardiac troponins. N Engl J Med 2005; 352: 98–100, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Panteghini M, Gerhardt W, Apple F S, Dati F, Ravkilde J, Wu A H. Quality specifications for cardiac troponin assays. Clin Chem Lab Med 2001; 39: 175–179, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Eriksson S, Ilva T, Becker C, Lund J, Porela P, Pulkki K, Voipio-Pulkki L M, Pettersson K. Comparison of cardiac troponin I immunoassays variably affected by circulating autoantibodies. Clin Chem 2005; 51: 848–855, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ilva T, Eriksson S, Lund J, Porela P, Mustonen H, Pettersson K, Pulkki K, Voipio-Pulkki L M. Improved early risk stratification and diagnosis of myocardial infarction, using a novel troponin I assay concept. Eur J Clin Invest 2005; 35: 112–116, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Fitzmaurice T F, Brown C, Rifai N, Wu A H, Yeo K T. False increase of cardiac troponin I with heterophilic antibodies. Clin Chem 1998; 44: 2212–2214, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Yeo K T, Storm C A, Li Y, Jayne J E, Brough T, Quinn-Hall K S, Fitzmaurice T F. Performance of the enhanced Abbott AxSYM cardiac troponin I reagent in patients with heterophilic antibodies. Clin Chim Acta 2000; 292: 13–23, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Fleming S M, O'Byrne L, Finn J, Grimes H, Daly K M. False-positive cardiac troponin I in a routine clinical population. Am J Cardiol 2002; 89: 1212–1215, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Dasgupta A, Banerjee S K, Datta P. False-positive troponin I in the MEIA due to the presence of rheumatoid factors in serum. Elimination of this interference by using a polyclonal antisera against rheumatoid factors. Am J Clin Pathol 1999; 112: 753–756, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Krahn J, Parry D M, Leroux M, Dalton J. High percentage of false positive cardiac troponin I results in patients with rheumatoid factor. Clin Biochem 1999; 32: 477–480, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Onuska K D, Hill S A. Effect of rheumatoid factor on cardiac troponin I measurement using two commercial measurement systems [Letter]. Clin Chem 2000; 46: 307–308, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Knoblock R J, Lehman C M, Smith R A, Apple F S, Roberts W L. False-positive AxSYM cardiac troponin I results in a 53-year-old woman. Arch Pathol Lab Med 2002; 126: 606–609, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Plebani M, Mion M, Altinier S, Girotto M A, Baldo G, Zaninotto M. False-positive troponin I attributed to a macrocomplex. Clin Chem 2002; 48: 677–679, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lagneau F, Beyne P, Letteron P, Laperche T, Marty J. Fluid therapy directly interferes with immunoassay for cardiac troponin I. Intensive Care Med 1999; 25: 625–627, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Kazmierczak S C, Catrou P G, Briley K P. Transient nature of interference effects from heterophile antibodies: Examples of interference with cardiac marker measurements. Clin Chem Lab Med 2000; 38: 33–39, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Parry D M, Krahn J, Leroux M, Dalton J. False positive analytical interference of cardiac troponin I assays: An important consideration for method selection. Clin Biochem 1999; 32: 667–669, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Kim W J, Laterza O F, Hock K G, Pierson-Perry J F, Kaminski D M, Mesguich M, Braconnier F, Zimmermann R, Zaninotto M, Plebani M, Hanna A, Cembrowski G S, Scott M G. Performance of a revised cardiac troponin method that minimizes interferences from heterophilic antibodies. Clin Chem 2002; 48: 1028–1034, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Dasgupta A, Wells A, Biddle D A. Negative interference of bilirubin and hemoglobin in the MEIA troponin I assay but not in the MEIA CK-MB assay. J Clin Lab Anal 2001; 15: 76–80, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bohner J, von Pape K W, Hannes W, Stegmann T. False-negative immunoassay results for cardiac troponin I probably due to circulating troponin I autoantibodies [Letter]. Clin Chem 1996; 42: 2046, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Tate J R, Heathcote D, Rayfield J, Hickman P E. The lack of standardization of cardiac troponin I assay systems. Clin Chim Acta 1999; 284: 141–149, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Newman D J, Olabiran Y, Bedzyk W D, Chance S, Gorman E G, Price C P. Impact of antibody specificity and calibration material on the measure of agreement between methods for cardiac troponin I. Clin Chem 1999; 45: 822–828, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Apple F S, Maturen A J, Mullins R E, Painter P C, Pessin-Minsley M S, Webster R A, Spray Flores J, DeCresce R, Fink D J, Buckley P M, Marsh J, Ricchiuti V, Christenson R H. Multicenter clinical and analytical evaluation of the AxSYM troponin-I immunoassay to assist in the diagnosis of myocardial infarction. Clin Chem 1999; 45: 206–212, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Tate J R, Heathcote D, Koerbin G, Thean G, Andriske D, Bonar J, Gill J. The harmonization of cardiac troponin I measurement is independent of sample time collection but is dependent on the source of calibrator. Clin Chim Acta 2002; 324: 13–23, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Christenson R H, Duh S H, Apple F S, Bodor G S, Bunk D M, Dalluge J, Panteghini M, Potter J D, Welch M J, Wu A HB, Kahn S E. Standardization of cardiac troponin I assays: Round robin of ten candidate reference materials. Clin Chem 2001; 47: 431–437, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bunk D, Dalluge J, Welch M. Heterogeneity in human cardiac troponin I standards. Anal Biochem 2000; 284: 191–200, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Antman E M, Tanasijevic M J, Thompson B, Schactman M, McCabe C H, Cannon C P, Fischer G A, Fung A Y, Thompson C, Wybenga D, Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342–1349, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Luscher M S, Thygesen K, Ravkilde J, Heickendorff L. Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. Circulation 1997; 96: 2578–2585, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Morrow D A, Rifai N, Tanasijevic M J, Wybenga D R, de Lemos J A, Antman E M. Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: Thrombolysis In Myocardial Infarction (TIMI) 11B substudy. Clin Chem 2000; 46: 453–460, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Apple F S, Wu A H, Jaffe A S. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: How to use existing assays clinically and for clinical trials. Am Heart J 2002; 144: 981–986, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Apple F S, Quist H E, Doyle P J, Otto A P, Murakami M M. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 2003; 49: 1331–1336, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Venge P, Johnston N, Lagerqvist B, Wallentin L, Lindahl B. Clinical and analytical performance of the Liaison cardiac troponin I assay in unstable coronary artery disease, and the impact of age on the definition of reference limits. A FRISC-II substudy. Clin Chem 2003; 49: 880–886, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Christenson R H, Cervelli D R, Bauer R S, Gordon M. Stratus CS cardiac troponin I method: Performance characteristics including imprecision at low concentrations. Clin Biochem 2004; 37: 679–683, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Panteghini M, Pagani F, Yeo K T, Apple F S, Christenson R H, Dati F, Mair J, Ravkilde J, Wu A H. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2004; 50: 327–332, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Peetz D, Hafner G, Lackner K J. Analytical characteristics of the AxSYM cardiac troponin I and creatine kinase MB assays. Clin Chem 2002; 48: 1110–1111, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Apple F S. Analytical issues for cardiac troponin. Prog Cardiovasc Dis 2004; 47: 189–195, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Clark G H, Kennon S R, Price C P. Evaluation of a new troponin I method on the Bayer Immuno 1 immunoassay analyser. J Immunoassay 1999; 20: 253–273, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sanhai W R, Romero L F, Hickey G, Ruttle D, Christenson R H. Performance characteristics of a revised cardiac Troponin I assay for the Opus plus immunoassay system. Clin Biochem 2001; 34: 579–582, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Pagani F, Stefini F, Panteghini M. Innotrac aio! Second-generation cardiac troponin I assay: Imprecision profile and other key characteristics for clinical use. Clin Chem 2004; 50: 1271–1272, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Apple F S, Murakami M M, Christenson R H, Campbell J L, Miller C J, Hock K G, Scott M G. Analytical performance of the i-STAT cardiac troponin I assay. Clin Chim Acta 2004; 345: 123–127, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Apple F S, Koplen B, Murakami M M. Preliminary evaluation of the Vitros ECi cardiac troponin I assay. Clin Chem 2000; 46: 572–574, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Apple F S, Quist H E, Murakami M M. Diagnostic and prognostic value of cardiac troponin I assays in patients admitted with symptoms suggestive of acute coronary syndrome. Arch Pathol Lab Med 2004; 128: 430–434, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Wu A H, Smith A, Christenson R H, Murakami M M, Apple F S. Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction. Clin Chim Acta 2004; 346: 211–219, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pagani F, Stefini F, Micca G, Toppino M, Manoni F, Romano L, Hoffer P, Iervasi A, Caputo M, Dorizzi R, Zucchelli G, Panteghini M. Multicenter evaluation of the TOSOH AIA-pack second-generation cardiac troponin I assay. Clin Chem 2004; 50: 1707–1709, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Venge P, Lagerqvist B, Diderholm E, Lindahl B, Wallentin L. Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a Fragmin during Instability in Coronary (FRISC) Artery Disease Study Group II substudy). Am J Cardiol 2002; 89: 1035–1041, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Morrow D A, Rifai N, Sabatine M S, Ayanian S, Murphy S A, de Lemos J A, Braunwald E, Cannon C P. Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes. Clin Chem 2003; 49: 1396–1398, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Kontos M C, Shah R, Fritz L M, Anderson F P, Tatum J L, Ornato J P, Jesse R L. Implication of different cardiac troponin I levels for clinical outcomes and prognosis of acute chest pain patients. J Am Coll Cardiol 2004; 43: 958–965, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Morrow D A. Evidence-based decision limits for cardiac troponin: Low-level elevation and prognosis. Am Heart J 2004; 148: 739–742, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Mair J. Progress in myocardial damage detection: New biochemical markers for clinicians. Crit Rev Clin Lab Sci 1997; 34: 1–66, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ingwall J S, Kramer M F, Fifer M A, Lorell B H, Shemin R, Grossman W, Allen P D. The creatine kinase system in normal and diseased human myocardium. N Engl J Med 1985; 313: 1050–1054, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Adams J E, 3rd, Schechtman K B, Landt Y, Ladenson J H, Jaffe A S. Comparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I. Clin Chem 1994; 40: 1291–1295, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Henderson A R, Krishnan S, Webb S, Cheung C M, Nazir D J, Richardson H. Proficiency testing of creatine kinase and creatine kinase-2: The experience of the Ontario Laboratory Proficiency Testing Program. Clin Chem 1998; 44: 124–133, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Christenson R H, Vaidya H, Landt Y, Bauer R S, Green S F, Apple F A, Jacob A, Magneson G R, Nag S, Wu A H, Azzazy H M. Standardization of creatine kinase-MB (CK-MB) mass assays: The use of recombinant CK-MB as a reference material. Clin Chem 1999; 45: 1414–1423, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Gibler W B, Lewis L M, Erb R E, Makens P K, Kaplan B C, Vaughn R H, Biagini A V, Blanton J D, Campbell W B. Early detection of acute myocardial infarction in patients presenting with chest pain and nondiagnostic ECGs: Serial CK-MB sampling in the emergency department. Ann Emerg Med 1990; 19: 1359–1366, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Apple F S, Murakami M M. Cardiac troponin and creatine kinase MB monitoring during in-hospital myocardial reinfarction. Clin Chem 2005; 51: 460–463, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Van Nieuwenhoven F A, Kleine A H, Wodzig K WH, Hermens W T, Kragten H A, Maessen J G, Punt C D, Van Dieijen M P, Van Der Vusse G J, Glatz J FC. Discrimination between myocardial and skeletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acid–binding protein. Circulation 1995; 92: 2848–2854, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kragten J, van Nieuwenhoven F, van Dieijen-Visser M, Theunissen P, Hermens W, Glatz J. Distribution of myoglobin and fatty acid-binding protein in human cardiac autopsies. Clin Chem 1996; 42: 337–338, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Gorski J, Hermens W T, Borawski J, Mysliwiec M, Glatz J F. Increased fatty acid-binding protein concentration in plasma of patients with chronic renal failure. Clin Chem 1997; 43: 193–195, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Christenson R H, Duh S H. Evidence based approach to practice guides and decision thresholds for cardiac markers. Scand J Clin Lab Invest Suppl 1999; 230: 90–102, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Azzazy H ME, Christenson R H. Cardiac markers of acute coronary syndromes: Is there a case for point-of-care testing?. Clin Biochem 2002; 35: 13–27, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sallach S M, Nowak R, Hudson M P, Tokarski G, Khoury N, Tomlanovich M C, Jacobsen G, de Lemos J A, McCord J. A change in serum myoglobin to detect acute myocardial infarction in patients with normal troponin I levels. Am J Cardiol 2004; 94: 864–867, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Eggers K M, Oldgren J, Nordenskjold A, Lindahl B. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: Limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J 2004; 148: 574–581, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Glatz J F, van der Vusse G J. Cellular fatty acid-binding proteins: Their function and physiological significance. Prog Lipid Res 1996; 35: 243–282, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zschiesche W, Kleine A H, Spitzer E, Veerkamp J H, Glatz J F. Histochemical localization of heart-type fatty-acid binding protein in human and murine tissues. Histochem Cell Biol 1995; 103: 147–156, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Glatz J F, van Bilsen M, Paulussen R J, Veerkamp J H, van der Vusse G J, Reneman R S. Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox. Biochim Biophys Acta 1988; 961: 148–152, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wodzig K W, Kragten J A, Hermens W T, Glatz J F, van Dieijen-Visser M P. Estimation of myocardial infarct size from plasma myoglobin or fatty acid-binding protein. Influence of renal function. Eur J Clin Chem Clin Biochem 1997; 35: 191–198, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Pelsers M M, Chapelle J P, Knapen M, Vermeer C, Muijtjens A M, Hermens W T, Glatz J F. Influence of age and sex and day-to-day and within-day biological variation on plasma concentrations of fatty acid-binding protein and myoglobin in healthy subjects. Clin Chem 1999; 45: 441–443, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pagani F, Bonora R, Bonetti G, Panteghini M. Evaluation of a sandwich enzyme-linked immunosorbent assay for the measurement of serum heart fatty acid-binding protein. Ann Clin Biochem 2002; 39: 404–405, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Liuzzo G, Biasucci L M, Gallimore J R, Grillo R L, Rebuzzi A G, Pepys M B, Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417–424, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ridker P M, Rifai N, Pfeffer M A, Sacks F M, Moye L A, Goldman S, Flaker G C, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839–844, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ridker P M, Rifai N, Pfeffer M A, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230–235, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ridker P M, Cushman M, Stampfer M J, Tracy R P, Hennekens C H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–979, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ridker P M, Hennekens C H, Buring J E, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–843, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ridker P M, Rifai N, Clearfield M, Downs J R, Weis S E, Miles J S, Gotto A M, Jr. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959–1965, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ridker P M, Rifai N, Rose L, Buring J E, Cook N R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557–1565, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zwaka T P, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation 2001; 103: 1194–1197, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wang C H, Li S H, Weisel R D, Fedak P W, Dumont A S, Szmitko P, Li R K, Mickle D A, Verma S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 1783–1790, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Verma S, Wang C H, Li S H, Dumont A S, Fedak P W, Badiwala M V, Dhillon B, Weisel R D, Li R K, Mickle D A, Stewart D J. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913–919, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pasceri V, Willerson J T, Yeh E T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165–2168, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pasceri V, Cheng J S, Willerson J T, Yeh E T. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531–2534, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cermak J, Key N S, Bach R R, Balla J, Jacob H S, Vercellotti G M. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513–520, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Devaraj S, Xu D Y, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107: 398–404, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, McGeer E G, McGeer P L. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158: 1039–1051, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Calabro P, Willerson J T, Yeh E T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003; 108: 1930–1932, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yeh E T, Willerson J T. Coming of age of C-reactive protein: Using inflammation markers in cardiology. Circulation 2003; 107: 370–371, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Meier-Ewert H K, Ridker P M, Rifai N, Price N, Dinges D F, Mullington J M. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 2001; 47: 426–430, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ockene I S, Matthews C E, Rifai N, Ridker P M, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001; 47: 444–450, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rus H G, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996; 127: 263–271, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Bohm M, Nickenig G. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 2004; 94: 534–541, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen P T, Kaartinen M, Nussberger J, Harringer W, Drexler H. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372–1378, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Biasucci L M, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi A G, Ginnetti F, Dinarello C A, Maseri A. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999; 99: 2079–2084, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: Effects of an early invasive or noninvasive strategy. JAMA 2001; 286: 2107–2113, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ridker P M, Rifai N, Stampfer M J, Hennekens C H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767–1772, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bennet A M, Prince J A, Fei G Z, Lyrenas L, Huang Y, Wiman B, Frostegard J, Faire U. Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction. Atherosclerosis 2003; 171: 359–367, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Haddy N, Sass C, Droesch S, Zaiou M, Siest G, Ponthieux A, Lambert D, Visvikis S. IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: The STANISLAS cohort. Atherosclerosis 2003; 170: 277–283, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Girasole G, Jilka R L, Passeri G, Boswell S, Boder G, Williams D C, Manolagas S C. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 1992; 89: 883–891, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Arvidson N G, Gudbjornsson B, Elfman L, Ryden A C, Totterman T H, Hallgren R. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 521–524, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Azzawi M, Hasleton P. Tumour necrosis factor alpha and the cardiovascular system: Its role in cardiac allograft rejection and heart disease. Cardiovasc Res 1999; 43: 850–859, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ridker P M, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149–2153, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cesari M, Penninx B W, Newman A B, Kritchevsky S B, Nicklas B J, Sutton-Tyrrell K, Rubin S M, Ding J, Simonsick E M, Harris T B, Pahor M. Inflammatory markers and onset of cardiovascular events: Results from the Health ABC study. Circulation 2003; 108: 2317–2322, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gearing A J, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506–512, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Garton K J, Gough P J, Philalay J, Wille P T, Blobel C P, Whitehead R H, Dempsey P J, Raines E W. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem 2003; 278: 37459–37464, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Whiteman S C, Bianco A, Knight R A, Spiteri M A. Human rhinovirus selectively modulates membranous and soluble forms of its intercellular adhesion molecule-1 (ICAM-1) receptor to promote epithelial cell infectivity. J Biol Chem 2003; 278: 11954–11961, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• O'Brien K D, McDonald T O, Chait A, Allen M D, Alpers C E. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996; 93: 672–682, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ridker P M, Hennekens C H, Roitman-Johnson B, Stampfer M J, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88–92, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Luc G, Arveiler D, Evans A, Amouyel P, Ferrieres J, Bard J M, Elkhalil L, Fruchart J C, Ducimetiere P. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: The PRIME Study. Atherosclerosis 2003; 170: 169–176, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• de Lemos J A, Hennekens C H, Ridker P M. Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J Am Coll Cardiol 2000; 36: 423–426, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Rupprecht H J, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104: 1336–1342, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Haim M, Tanne D, Boyko V, Reshef T, Goldbourt U, Leor J, Mekori Y A, Behar S. Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study. J Am Coll Cardiol 2002; 39: 1133–1138, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191–203, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Klebanoff S J. Myeloperoxidase: Friend and foe. J Leukoc Biol 2005; 77: 598–625, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sugiyama S, Okada Y, Sukhova G K, Virmani R, Heinecke J W, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001; 158: 879–891, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Fu X, Kassim S Y, Parks W C, Heinecke J W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001; 276: 41279–41287, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Eiserich J P, Baldus S, Brennan M L, Ma W, Zhang C, Tousson A, Castro L, Lusis A J, Nauseef W M, White C R, Freeman B A. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002; 296: 2391–2394, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Podrez E A, Febbraio M, Sheibani N, Schmitt D, Silverstein R L, Hajjar D P, Cohen P A, Frazier W A, Hoff H F, Hazen S L. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest 2000; 105: 1095–1108, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zheng L, Nukuna B, Brennan M L, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox P L, Ischiropoulos H, Smith J D, Kinter M, Hazen S L. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114: 529–541, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Baldus S, Eiserich J P, Mani A, Castro L, Figueroa M, Chumley P, Ma W, Tousson A, White C R, Bullard D C, Brennan M L, Lusis A J, Moore K P, Freeman B A. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest 2001; 108: 1759–1770, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zhang R, Brennan M L, Fu X, Aviles R J, Pearce G L, Penn M S, Topol E J, Sprecher D L, Hazen S L. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286: 2136–2142, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Baldus S, Heeschen C, Meinertz T, Zeiher A M, Eiserich J P, Munzel T, Simoons M L, Hamm C W. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440–1445, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Brennan M L, Penn M S, Van Lente F, Nambi V, Shishehbor M H, Aviles R J, Goormastic M, Pepoy M L, McErlean E S, Topol E J, Nissen S E, Hazen S L. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595–1604, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Henn V, Steinbach S, Buchner K, Presek P, Kroczek R A. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047–1054, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pietravalle F, Lecoanet-Henchoz S, Blasey H, Aubry J P, Elson G, Edgerton M D, Bonnefoy J Y, Gauchat J F. Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem 1996; 271: 5965–5967, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mach F, Schonbeck U, Bonnefoy J Y, Pober J S, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: Induction of collagenase, stromelysin, and tissue factor. Circulation 1997; 96: 396–399, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mach F, Schonbeck U, Sukhova G K, Bourcier T, Bonnefoy J Y, Pober J S, Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931–1936, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Mach F, Sukhova G K, Murphy C, Bonnefoy J Y, Fabunmi R P, Libby P. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: A role for CD40 signaling in plaque rupture?. Circ Res 1997; 81: 448–454, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Mach F, Sukhova G K, Herman M, Graber P, Kehry M R, Libby P. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol 2000; 156: 7–14, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Andre P, Prasad K S, Denis C V, He M, Papalia J M, Hynes R O, Phillips D R, Wagner D D. CD40L stabilizes arterial thrombi by a beta3 integrin—dependent mechanism. Nat Med 2002; 8: 247–252, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Heeschen C, Dimmeler S, Hamm C W, van den Brand M J, Boersma E, Zeiher A M, Simoons M L. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104–1111, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Varo N, de Lemos J A, Libby P, Morrow D A, Murphy S A, Nuzzo R, Gibson C M, Cannon C P, Braunwald E, Schonbeck U. Soluble CD40L: Risk prediction after acute coronary syndromes. Circulation 2003; 108: 1049–1052, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Varo N, Libby P, Buring J, Ridker P M. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266–2268, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Conde I D, Kleiman N S. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 2575–2577, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico M G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991; 88: 9267–9271, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy J A, Hooper A, Priller J, De Klerck B, Compernolle V, Daci E, Bohlen P, Dewerchin M, Herbert J M, Fava R, Matthys P, Carmeliet G, Collen D, Dvorak H F, Hicklin D J, Carmeliet P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8: 831–840, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: Novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003; 1: 1356–1370, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Heeschen C, Dimmeler S, Fichtlscherer S, Hamm C W, Berger J, Simoons M L, Zeiher A M. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 2004; 291: 435–441, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lin T M, Galbert S P, Kiefer D, Spellacy W N, Gall S. Characterization of four human pregnancy-associated plasma proteins. Am J Obstet Gynecol 1974; 118: 223–236, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lin T M, Halbert S P, Spellacy W N. Measurement of pregnancy-associated plasma proteins during human gestation. J Clin Invest 1974; 54: 576–582, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wald N, Stone R, Cuckle H S, Grudzinskas J G, Barkai G, Brambati B, Teisner B, Fuhrmann W. First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome. BMJ 1992; 305: 28, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Oxvig C, Sand O, Kristensen T, Gleich G J, Sottrup-Jensen L. Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein. J Biol Chem 1993; 268: 12243–12246, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Boldt H B, Overgaard M T, Laursen L S, Weyer K, Sottrup-Jensen L, Oxvig C. Mutational analysis of the proteolytic domain of pregnancy-associated plasma protein-A (PAPP-A): Classification as a metzincin. Biochem J 2001; 358: 359–367, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Lawrence J B, Oxvig C, Overgaard M T, Sottrup-Jensen L, Gleich G J, Hays L G, Yates J R, 3rd, Conover C A. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA 1999; 96: 3149–3153, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Laursen L S, Overgaard M T, Nielsen C G, Boldt H B, Hopmann K H, Conover C A, Sottrup-Jensen L, Giudice L C, Oxvig C. Substrate specificity of the metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) assessed by mutagenesis and analysis of synthetic peptides: Substrate residues distant from the scissile bond are critical for proteolysis. Biochem J 2002; 367: 31–40, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Bayes-Genis A, Conover C A, Schwartz R S. The insulin-like growth factor axis: A review of atherosclerosis and restenosis. Circ Res 2000; 86: 125–130, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Overgaard M T, Glerup S, Boldt H B, Rodacker V, Olsen I M, Christiansen M, Sottrup-Jensen L, Giudice L C, Oxvig C. Inhibition of proteolysis by the proform of eosinophil major basic protein (proMBP) requires covalent binding to its target proteinase. FEBS Lett 2004; 560: 147–152, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Conover C A, Overgaard M T, Bailey K R, Christiansen M, Holmes D R, Jr, Virmani R, Oxvig C, Schwartz R S. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001; 345: 1022–1029, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Resch Z T, Chen B K, Bale L K, Oxvig C, Overgaard M T, Conover C A. Pregnancy-associated plasma protein A gene expression as a target of inflammatory cytokines. Endocrinology 2004; 145: 1124–1129, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Conover C A, Bale L K, Harrington S C, Resch Z T, Overgaard M T, Oxvig C. Cytokine stimulation of pregnancy-associated plasma protein A expression in human coronary artery smooth muscle cells: Inhibition by resveratrol. Am J Physiol Cell Physiol 2006; 290: C183–C188, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Schwartz R S, Lewis D A, Overgaard M T, Christiansen M, Oxvig C, Ashai K, Holmes D R, Jr, Conover C A. Insulin-like growth factor binding protein-4 protease produced by smooth muscle cells increases in the coronary artery after angioplasty. Arterioscler Thromb Vasc Biol 2001; 21: 335–341, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Chen B K, Leiferman K M, Pittelkow M R, Overgaard M T, Oxvig C, Conover C A. Localization and regulation of pregnancy-associated plasma protein A expression in healing human skin. J Clin Endocrinol Metab 2003; 88: 4465–4471, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Khosravi J, Diamandi A, Krishna R G, Bodani U, Mistry J, Khaja N. Pregnancy associated plasma protein-A: Ultrasensitive immunoassay and determination in coronary heart disease. Clin Biochem 2002; 35: 531–538, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lund J, Qin Q P, Ilva T, Pettersson K, Voipio-Pulkki L M, Porela P, Pulkki K. Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003; 108: 1924–1926, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Heeschen C, Dimmeler S, Hamm C W, Fichtlscherer S, Simoons M L, Zeiher A M. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: Comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol 2005; 45: 229–237, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Stulc T, Malbohan I, Malik J, Fialova L, Soukupova J, Ceska R. Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: The effect of atorvastatin treatment. Am Heart J 2003; 146: 1060–1063, [CSA], [CROSSREF]
   Google Scholar
• Aso Y, Okumura K, Wakabayashi S, Takebayashi K, Taki S, Inukai T. Elevated pregnancy-associated plasma protein-a in sera from type 2 diabetic patients with hypercholesterolemia: Associations with carotid atherosclerosis and toe-brachial index. J Clin Endocrinol Metab 2004; 89: 5713–5717, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Cosin-Sales J, Christiansen M, Kaminski P, Oxvig C, Overgaard M T, Cole D, Holt D W, Kaski J C. Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris. Circulation 2004; 109: 1724–1728, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cosin-Sales J, Kaski J C, Christiansen M, Kaminski P, Oxvig C, Overgaard M T, Cole D, Holt D W. Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. Eur Heart J 2005; 26: 2093–2098, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Qin Q P, Laitinen P, Majamaa-Voltti K, Eriksson S, Kumpula E K, Pettersson K. Release patterns of pregnancy associated plasma protein A (PAPP-A) in patients with acute coronary syndromes. Scand Cardiovasc J 2002; 36: 358–361, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lund J, Qin Q P, Ilva T, Nikus K, Eskola M, Porela P, Kokkala S, Pulkki K, Pettersson K, Voipio-Pulkki L M. Pregnancy associated plasma protein A: A biomarker in acute ST-elevation myocardial infarction (STEMI). Ann Med 2006; 38: 221–228, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Qin Q P, Kokkala S, Lund J, Tamm N, Voipio-Pulkki L M, Pettersson K. Molecular distinction of circulating pregnancy-associated plasma protein A in myocardial infarction and pregnancy. Clin Chem 2005; 51: 75–83, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Qin Q, Kokkala S, Lund J, Tamm N, Qin X, Lepäntalo M, Pettersson K. Immunoassays developed for pregnancy-associated plasma protein A (PAPP-A) in pregnancy may not recognize PAPP-A in acute coronary syndromes. Clin Chem 2006; 52: 398–404, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Bar-Or D, Lau E, Winkler J V. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia—a preliminary report. J Emerg Med 2000; 19: 311–315, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 2001; 268: 42–47, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Christenson R H, Duh S H, Sanhai W R, Wu A H, Holtman V, Painter P, Branham E, Apple F S, Murakami M, Morris D L. Characteristics of an Albumin Cobalt Binding Test for assessment of acute coronary syndrome patients: A multicenter study. Clin Chem 2001; 47: 464–470, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bhagavan N V, Lai E M, Rios P A, Yang J, Ortega-Lopez A M, Shinoda H, Honda S A, Rios C N, Sugiyama C E, Ha C E. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 2003; 49: 581–585, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sinha M K, Roy D, Gaze D C, Collinson P O, Kaski J C. Role of “Ischemia modified albumin,” a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004; 21: 29–34, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Roy D, Quiles J, Aldama G, Sinha M, Avanzas P, Arroyo-Espliguero R, Gaze D, Collinson P, Carlos Kaski J. Ischemia Modified Albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T. Int J Cardiol 2004; 97: 297–301, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sabatine M S. When prognosis precedes diagnosis: Putting the cart before the horse. CMAJ 2005; 172: 1697–1698, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Apple F S, Wu A H, Mair J, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson R H, Mockel M, Danne O, Jaffe A S. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51: 810–824, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Spector A A. Fatty acid binding to plasma albumin. J Lipid Res 1975; 16: 165–179, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Richieri G V, Ogata R T, Kleinfeld A M. A fluorescently labeled intestinal fatty acid binding protein. Interactions with fatty acids and its use in monitoring free fatty acids. J Biol Chem 1992; 267: 23495–23501, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Richieri G V, Ogata R T, Kleinfeld A M. The measurement of free fatty acid concentration with the fluorescent probe ADIFAB: A practical guide for the use of the ADIFAB probe. Mol Cell Biochem 1999; 192: 87–94, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Kleinfeld A M, Prothro D, Brown D L, Davis R C, Richieri G V, DeMaria A. Increases in serum unbound free fatty acid levels following coronary angioplasty. Am J Cardiol 1996; 78: 1350–1354, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Apple F S, Kleinfeld A M, Adams J. Unbound free fatty acid concentrations are increased in cardiac ischemia. Clin Proteomics 2004; 1: 41–44, [CSA]
   Google Scholar
• Chiang T M. Activation of phospholipase D in human platelets by collagen and thrombin and its relationship to platelet aggregation. Biochim Biophys Acta 1994; 1224: 147–155, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Danne O, Mockel M, Lueders C, Mugge C, Zschunke G A, Lufft H, Muller C, Frei U. Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol 2003; 91: 1060–1067, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar